Puma Biotechnology

July 2, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 7, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 3, 2024 - Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
Read

June 2, 2024 - Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Read

May 28, 2024 - Puma Biotechnology to Join Russell 3000 Index
Read

May 23, 2024 - Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
Read

May 2, 2024 - Puma Biotechnology Reports First Quarter Financial Results
Read

April 18, 2024 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Read

April 3, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Mar. 20, 2024 - Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Read

Feb. 29, 2024 - Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Read

Feb. 27, 2024< - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Feb. 22, 2024 - Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
Read

Feb. 15, 2024 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Read

Feb. 13, 2024 - Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
Read

Jan. 11, 2024 - Puma Biotechnology to Present at B. Riley Securities 4 th Annual Oncology Conference
Read

2024 News Releases